Search clinical trials for: Cemiplimab-Rwlc

Total 152 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...

United States
University of Southern California
National Cancer Institute (NCI)

Recruiting

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Recurrent Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell Carcinoma | Stage I Skin Cancer | Stage II Skin Cancer | Stage III Skin Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals

Terminated

Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

Cutaneous Squamous Cell Carcinoma of the Head and Neck | Cutaneous Squamous Cell Carcinoma

United States
University of Miami
Regeneron Pharmaceuticals

Withdrawn

Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma | HNSCC | Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of Hypopharynx
H. Lee Moffitt Cancer Center and Research Institute
Regeneron Pharmaceuticals; Sanofi-Synthelabo

Recruiting

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Peter MacCallum Cancer Centre, Australia
Sanofi; Regeneron Pharmaceuticals; Monash University; University of Adelaide; University...

Recruiting

Deep sequencIng in Cutaneous Squamous CEll caRciNomas (DISCERN)

Neoplasms | Cutaneous Squamous Cell Carcinoma of the Head and Neck | Non-melanoma Skin Cancer | Cutaneous Squamous Cell Carcinoma

Australia
Emory University
National Cancer Institute (NCI)

Recruiting

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Metastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma

United States
Alaunos Therapeutics

Completed

Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma

Glioblastoma

United States
M.D. Anderson Cancer Center

Terminated

SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
Marcelo Bonomi

Recruiting

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditions

United States
Baptist Health South Florida
Regeneron Pharmaceuticals

Withdrawn

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Advanced Squamous Cell Carcinoma

United States
Thomas Jefferson University

Recruiting

Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Locally Advanced Basal Cell Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Advanced Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Locally Advanced Dedifferentiated Liposarcoma | Unresectable Dedifferentiated...

United States
Ottawa Hospital Research Institute
Ontario Institute for Cancer Research

Not yet recruiting

PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer

Breast Cancer

Canada
University of Southern California
National Cancer Institute (NCI)

Recruiting

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Advanced Malignant Skin Neoplasm | Metastatic Malignant Skin Neoplasm

United States
Regeneron Pharmaceuticals
Pacific Pediatric Neuro-Oncology Consortium

Terminated

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

High Grade Glioma | Diffuse Intrinsic Pontine Glioma | Relapsed Solid Tumor | Refractory Solid Tumor | Relapsed Central Nervous System Tumor | Refractory Central Nervous System Tumor

United States
Regeneron Pharmaceuticals
Sanofi

No longer available

Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma
Reinhard Dummer
Sanofi; Sun Pharmaceutical Industries Ltd

Recruiting

Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Basal Cell Carcinoma

Switzerland
Regeneron Pharmaceuticals

Completed

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma

United States, Spain, France, Italy, Australia, Germany, Brazil, Greece
Regeneron Pharmaceuticals

Active, not recruiting

CemiplimAb Survivorship Epidemiology (CASE)

Basal Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States, Puerto Rico
Regeneron Pharmaceuticals
Sanofi

Completed

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

Carcinoma, Basal Cell

United States, Canada, France, Italy, Spain, Germany, Belgium, Austria, Greece, Switzerland
Regeneron Pharmaceuticals
Sanofi

Completed

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)

Melanoma

Korea, Republic of, Serbia, Netherlands, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Recurrent Squamous Cell Carcinoma of Head | Recurrent Squamous Cell Carcinoma of Neck | Metastatic Squamous Cell Carcinoma of Head | Metastatic Squamous Cell Carcinoma Neck

Korea, Republic of, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Malignancies

United States, Korea, Republic of, Australia, Ireland, United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Advanced Solid Tumor | Metastatic Solid Tumor

Netherlands
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies (CLIO-1)

Relapsed/Refractory Aggressive B-Cell Lymphoma

United States, Germany, Spain
Dana-Farber Cancer Institute
Astellas Pharma Inc; Regeneron Pharmaceuticals

Active, not recruiting

ASP8374 + Cemiplimab in Recurrent Glioma

Glioblastoma | Recurrent Glioblastoma

United States
Sanofi

Terminated

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Malignant Solid Tumor

France, Spain, Australia, Belgium, Italy, United Kingdom, Taiwan, Estonia, Netherlands, Korea, Republic of, United States, Canada, Germany
Regeneron Pharmaceuticals
Sanofi

Recruiting

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Regeneron Pharmaceuticals

Recruiting

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Recurrent Endometrial Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer | Recurrent Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Italy, United Kingdom, Netherlands, Belgium, Australia, France, Israel
Sanofi
BioNTech RNA Pharmaceuticals GmbH

Terminated

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Metastatic Neoplasm

France, Spain, United States, Belgium, Germany, Netherlands
Regeneron Pharmaceuticals
Sanofi

Terminated

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

Non-small Cell Lung Cancer

United States, Italy, Lithuania
Sanofi

Terminated

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Prostate Cancer | Non-small Cell Lung Cancer

Taiwan, United States, France, Italy, United Kingdom
Regeneron Pharmaceuticals

Recruiting

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States, Australia, Georgia
Sanofi

Completed

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Plasma Cell Myeloma

France, Italy, Czechia, Greece, Spain, Canada, Australia, United States, Brazil, Hungary
Sanofi

Terminated

A Study of Isatuximab-based Therapy in Participants With Lymphoma

Lymphoma

Korea, Republic of, Portugal, France, Taiwan, Italy, Netherlands, Spain
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Non-small Cell Lung Cancer

United States, France, Korea, Republic of, Italy, Austria, China, Georgia, Greece, Ireland, Lithuania, Malaysia, Poland, Romania, Russian Federation, Slovakia, Thailand, Turkey, Ukraine
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers (COMBINE-EGFR-1)

Advanced Solid Tumors

United States, Turkey
Regeneron Pharmaceuticals

Active, not recruiting

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Advanced Non-small Cell Lung Cancer

United States
Regeneron Pharmaceuticals

Suspended

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Non-Small Cell Lung Cancer | Triple Negative Breast Cancer | Merkel Cell Carcinoma | Basal Cell Carcinoma | Oropharynx Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States, Australia
University Health Network, Toronto

Completed

Rehabilitation Planning Consult Phase II Trial (RPC-II)

Head and Neck Neoplasms

Canada
Arizona State University
Calm.com, Inc.

Completed

Incentivizing Meditation App Habit Formation

Stress | Adherence, Treatment

United States
University of Missouri-Columbia
American Academy of Sleep Medicine Foundation

Completed

Playing Cognitive Games For Older Adults With Insomnia (PLAY)

Insomnia

United States
Rakuten Medical, Inc.

Active, not recruiting

An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Metastatic Cutaneous Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma

United States
Regeneron Pharmaceuticals
Sanofi

Terminated

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Advanced Non-Small Cell Lung Carcinoma

United States, Belgium, France, Germany, Korea, Republic of, Poland, Spain, Taiwan, United Kingdom
University of Coimbra
Fundação para a Ciência e a Tecnologia

Completed

Mindful Moment: Feasibility and Preliminary Efficacy of a Web-based Mindful and Compassionate Parenting Training

Parenting Stress

Portugal
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

M1774 in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

Non-Small Cell Lung Cancer

Korea, Republic of, United States, Japan
Radboud University Medical Center
Genzyme Europe B.V.

Recruiting

Cemiplimab for Secondary Angiosarcomas

Metastasis | Locally Advanced Sarcoma | Secondary Angiosarcoma

Netherlands
BioNTech SE

Terminated

PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy) (PRO-MERIT)

Prostate Cancer

United States, Germany, United Kingdom, Hungary

Search clinical trials for: Cemiplimab-Rwlc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations